Aptinyx — Investor Presentation (June 2021)
34 slides from Aptinyx's investor presentation, Jun 15, 2021
Slide 1: Innovative Therapies for Disorders of the Brain and Nervous System
Innovative Therapies for Disorders of the Brain and Nervous System Corporate Presentation June 2021 Nasdaq: APTX
Slide 2: Forward-looking statements disclaimer
This presentation has been prepared by Aptinyx Inc. (“we,” ”us,” “our,” “Aptinyx,” or the “Company”) and is made for informational purposes only and does not constitute an offer to sell or a solicitation of an offer to buy securities, nor shall there be any sale of any securities in any state or jur
Slide 3: Passion. Learning. Advancing. How we define progress to impact patient lives
PA S S I O N . LEARNING.ADVANCING. THIS IS HOW WE DEFINE PROGRESS TO IMPACT PATIENT LIVES June 2021 3
Slide 4: Multiple near-term catalysts with Phase readouts starting 1H 2022
June 2021 Multiple near-term catalysts with 4 Phase 2 readouts starting 1H 2022 4 June 2021 4
Slide 5: Novel modulation of the NMDA receptor at a unique domain
June 2021 Aptinyx compounds work through novel modulation of the NMDA receptor at a unique domain distinct from existing drugs. 5 June 2021 This approach can result in optimal modulation of the NMDA receptor, achieving therapeutic activity while providing a favorable safety and tolerability profile
Slide 6: Our approach is multidimensional
Our approach is multidimensional Enhancing synaptic plasticity to achieve therapeutic effects across disease areas CHRONIC PAIN COGNITION PSYCHIATRY June 2021 6
Slide 7: Our mission: innovative therapies for challenging CNS disorders
June 2021 OUR MISSION is to discover and develop innovative therapies for challenging disorders of the brain and nervous system Breadth of activity and encouraging efficacy data across multiple CNS indications with high unmet medical need Differentiated safety profile observed across hundreds of hea
Slide 8: Experienced management team and board
Experienced management team and a board of highly regarded healthcare investors and leaders 8 Patrick Enright (Chairman) Founder & Managing Director BOARD OF DIRECTORS Rachel Sherman, MD, MPH Former FDA Principal Deputy Commissioner Henry Gosebruch EVP, Chief Strategy Officer, AbbVie Norbert Riedel,
Slide 9: The NMDA receptor: essential for normal CNS function
June 2021 The NMDA receptor Essential for normal CNS function NMDA receptors are widely distributed at all stages of development and play a critical role in higher level brain functions, including For decades, researchers have attempted to discover and develop compounds that target NMDA receptors NM
Slide 10: NMDA receptor modulation: a novel and differentiated approach
June 2021 NMDA receptor modulation: A novel and differentiated approach to restoring normal balance in the CNS NMDA receptor modulation: A novel and differentiated approach to restoring normal balance in ON OFF ANTAGONIST OVERACTIVATION INHIBITION AGONIST DISSOCIATION PSYCHOTOMIMETIC ABUSE LIABILITY
Slide 11: NMDAr modulation triggers a neurobiological cascade enhancing synaptic plasticity
Modulation of NMDAr with Aptinyx compounds triggers a neurobiological cascade and enhances synaptic plasticity—the foundation of neural cell communication LTP = long-term potentiation LTD = long-term depression Rapid receptor engagement Long-lasting effects on neural plasticity processes Learning Me
Slide 12: NMDAr modulator discovery platform has produced >1,000 unique compounds
NMDAr modulator discovery platform has produced > 1,000 unique compounds Molecules bind at a novel, distinct, newly characterized binding domain Molecules demonstrate high oral bioavailability and stability Molecules have diverse potency, activity, subtype selectivity, and pharmacology/biology profi
Slide 13: Advancing a pipeline of innovative CNS therapies
INDICATION PRECLINICAL/ IND ENABLING PHASE 1 PHASE 2 PHASE 3 REGISTRATION/ COMMERCIAL CHRONIC PAIN PROGRAM NYX-2925 Fibromyalgia Painful Diabetic Peripheral Neuropathy (DPN) PSYCHIATRY PROGRAM NYX-783 Post-Traumatic Stress Disorder (PTSD) NEUROLOGY PROGRAM NYX-458 Cognitive Impairment in Parkinson’s
Slide 14: NMDA receptors are key targets for CNS disorders with high unmet need
NMDA receptors are key targets for numerous CNS disorders with high unmet medical need June 2021 Representing vast commercial opportunity for Aptinyx product candidates Fibromyalgia Up to 15 million People affected in the United States PTSD > 8.5 million Painful DPN ~ 7.5 million Cognitive Impairmen
Slide 15: Fibromyalgia and painful DPN
June 2021 Fibromyalgia is one of the most common chronic pain conditions Painful DPN is one of the most common complications among patients suffering from diabetes, estimated to affect up to 30% of patients • Both are substantial market opportunities with no adequate therapeutic options Current trea
Slide 16: Addressing centralized chronic pain through NMDA receptor modulation
Seeking to address centralized chronic pain conditions through novel NMDA receptor modulation Central processing abnormalities are present in chronic pain conditions Some pain conditions are believed to be primarily centralized pain conditions – e.g., fibromyalgia, phantom limb pain NYX-2925 is desi
Slide 17: Dysregulation of central pain processing in fibromyalgia and painful DPN
June 2021 Dysregulation of central pain processing is evident in patients with fibromyalgia and painful DPN Representing strong scientific rationale for the potential of NYX-2925 Aberrant processing in fibromyalgia — which can be objectively observed with validated biomarkers — results in pain and o
Slide 18: Activity on biomarkers and patient reported outcomes across two Phase 2 studies
-2.9 -3.8 -9.6 PBO (wk2) 20mg (wk 4) 200mg (wk 6) -0.4 -0.5 -1.1 PBO (wk2) 20mg (wk 4) 200mg (wk 6) Activity observed on biomarkers and patient reported outcomes across two Phase 2 studies in patients with chronic pain conditions June 2021 FIBROMYALGIA NEUROIMAGING STUDY – N=22 NYX-2925 significantl
Slide 19: Phase 2b studies of NYX-2925 in fibromyalgia and painful DPN
PAINFUL DPN Advanced DPN population (4+ years) No concomitant analgesics Primary endpoint: Change in average daily pain on the Numerical Rating Scale (NRS) Other endpoints: Worst daily pain, daily sleep interference, pain on walking Phase 2b studies of NYX-2925 in 2 chronic pain indications: fibromy
Slide 20: Development summary of NYX-2925
Development summary of NYX-2925 for painful DPN and fibromyalgia ✓ CLEAR PRECLINICAL ACTIVITY – robust, long-lasting effects seen across various models of neuropathic pain ✓ COMPLETED THREE PHASE 1 STUDIES – favorable tolerability, PK, and CNS exposure observed, as well as evidence of activity and N
Slide 21: PTSD
50-66% also battle simultaneous addiction to alcohol and drugs Numerous causes of PTSD Elevated suicide rates among PTSD sufferers June 2021 PTSD Estimated lifetime prevalence of 6.8% ONLY 2 approved therapies both approved 20+ years ago Car accidents War combat Criminal assault Natural disaster Sex
Slide 22: Differentiated approach to targeting PTSD
ANTIDEPRESSANTS – Mood ANXIOLYTICS – Severe anxiety-related complications HYPNOTICS – Nightmares – Sleep disturbances Differentiated approach to targeting PTSD: Addressing the underlying learning & memory dysfunction June 2021 CURRENT APPROACHES Target symptoms OUR APPROACH Targets underlying dysfun
Slide 23: Proof-of-concept study with clinically meaningful improvements
Compelling proof-of-concept study completed with clinically meaningful improvements observed across endpoints June 2021 Large proportion of patients achieved a clinically meaningful response with 4 weeks of treatment Consistent improvements observed on CAPS-5 symptom cluster scores Improvements obse
Slide 24: NYX-783 clinically meaningful change on CAPS-5 Total score
43% 45% 74% Placebo (n=86) 10mg NYX-783 (n=20) 50mg NYX-783 (n=19) p=0.01 vs. placebo STAGE 1 (WEEK 4) CAPS-5 TOTAL SCORE – Clinically Reliable Change June 2021 NYX-783 exhibited clinically meaningful change from baseline on CAPS-5 Total score Significantly greater proportion of patients demonstrate
Slide 25: CAPS-5 changes in line with therapies currently used for PTSD
June 2021 Observed changes from baseline to week 4 on CAPS-5 Total score in-line with observed changes for therapies currently used to treat PTSD ++Only Sertraline and Paroxetine are approved by the FDA for use in PTSD – All other therapies listed are used off-label or are currently in development *
Slide 26: Final design of Phase 2b program following Type C meeting with FDA
Final design of Phase 2b program following Type C meeting with FDA 10-WEEK TREATMENT PERIOD ~300 patients - Civilian and military PTSD 10 weeks of daily treatment Randomized, parallel, double-blind design No concomitant PTSD pharmacotherapies (SSRIs) Primary endpoint: CAPS-5 Total score Key secondar
Slide 27: Development summary of NYX-783 for PTSD
Development summary of NYX-783 for PTSD June 2021 ✓ CLEAR PRECLINICAL ACTIVITY in fear extinction and other psychiatric models ✓ FAVORABLE TOLERABILITY, PK, AND CNS EXPOSURE demonstrated in completed Phase 1 study in humans ✓ COMPLETED PHASE 2 STUDY – NYX-783 exhibited symptom reduction and demonstr
Slide 28: Cognitive impairment in Parkinson's disease and Lewy body dementia
Cognitive impairment in Parkinson’s disease and dementia with Lewy bodies (together referred to as Lewy body dementia) 1 therapy approved to date, Exelon®, which has demonstrated limited benefit in patients June 2021 ~1.4 million people suffering from Lewy body dementia in the United States 15–20% o
Slide 29: NYX-458 enhances NMDA receptor activity
NYX-458 enhances NMDA receptor activity and has the potential to address cognitive impairment in α-synuclein disorders Alpha-synuclein increases in Parkinson’s disease and dementia with Lewy bodies result in decreased NMDAr activity CLEAR MECHANISTIC RATIONALE Parkinson’s disease and dementia with L
Slide 30: NYX-458 pro-cognitive activity in preclinical models
NYX-458 exhibits clear pro-cognitive activity in preclinical models, including translatable non-human primate model of Parkinson’s disease VARIABLE DELAYED RESPONSE (VDR) Activity observed across cognitive domains Recovered effects after re-induced impairment Sustained effects with repeat dosing Eff
Slide 31: Exploratory Phase 2 study of NYX-458
Phase 2 exploratory study of NYX-458 in cognitive impairment associated with Parkinson’s disease and dementia with Lewy bodies June 2021 Data from exploratory Phase 2 study expected 2H 2022 Placebo QD 12-WEEK TREATMENT PERIOD • 50-85 years of age • PD-MCI, PDD, DLB, MCI-LB • CGI-S at least 3 (mildly
Slide 32: Development summary of NYX-458
Development summary of NYX-458 for cognitive impairment in Parkinson’s disease and dementia with Lewy bodies ✓ CLEAR PRECLINICAL ACTIVITY in numerous rodent models ✓ REVERSAL OF COGNITIVE DEFICITS in translatable non-human primate model of Parkinson’s disease ✓ COMPLETED PHASE 1 STUDY – favorable to
Slide 33: Strong cash position with multiple upcoming catalysts
Supported by strong cash position with multiple upcoming catalysts across programs Data readout from Phase 2b fibromyalgia study – 1H 2022 Data readout from Phase 2b painful DPN study – 1H 2022 NYX-2925 in CHRONIC PAIN NYX-458 in COGNITIVE IMPAIRMENT Data readout from Phase 2a Parkinson’s disease an
Slide 34: NMDA receptors implicated in a variety of neurological and psychiatric disorders
NMDA receptors have been implicated in the pathophysiology of a variety of neurological and psychiatric disorders Alzheimer’s Disease Depression Bipolar Disorder Substance Abuse Autism Spectrum Disorders Schizophrenia Cerebral Ischemia Huntington’s Disease Traumatic Brain Injury Anti-NMDAR Encephali